Vaccine Adjuvant Market is expected to reach US$ 6,931.55 million by 2030

Mineral Salt Adjuvant Segment to Hold Significant Share of Vaccine Adjuvant Market During 2022–2030  

According to our latest study on "Vaccine Adjuvant Market Forecast to 2030 – Global Analysis – Adjuvant Class and Type," the vaccine adjuvant market value is expected to reach US$ 6,931.55 million by 2030 from US$ 2,482.39 million in 2022. The report emphasizes the key factors driving the market and prominent players' developments. The occurrence of infectious disease outbreaks and pandemics and regulatory approvals of veterinary vaccine adjuvants are the key factors driving the market development. However, product recall and adverse effects hamper the growth of the vaccine adjuvant market.  

Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants are indicated for use in human vaccines. They are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone. Mineral salt adjuvant formulation at the inflammatory site produces a fast immune response by releasing proinflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.

Emulsion adjuvants such as surfactants are tensioactive compounds containing emulsion. Acting as immunostimulant adjuvants, these compounds are derived from the plant Quillaja saponaria. Five tensioactive adjuvants with "saponins" have been cleared for human use for parenteral administration. They are tensioactive glycosides containing a hydrophobic nucleus of a triterpenoid structure with a carbohydrate chain linked to the nucleus.

Vaccine Adjuvant Market, by Type:

Based on type, the vaccine adjuvant market is bifurcated into human vaccine adjuvants and veterinary vaccine adjuvants. The human vaccine adjuvant segment held a larger market share in 2022, which is anticipated to register a higher CAGR of 14.0% during 2022–2023. According to the National Institute of Health (NIH) report, adjuvants help antigens induce an early, high, and long-lasting immune response, saving production costs. Examples of human vaccine adjuvants include aluminum hydroxide and aluminum phosphate, calcium phosphate, and oil emulsions.

Much progress has been made in the development, isolation, and chemical synthesis of alternative adjuvants, such as derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS21, MF-59, and immunostimulating complexes (ISCOMS). Several top manufacturers develop human adjuvant vaccines. SEPPIC offers injectable vaccine adjuvants for formulating effective therapeutic vaccines. These ready-to-use oil-based adjuvants manufacture stable emulsions by mixing with antigens in an aqueous phase. SEPPIC's MONTANIDE ISA 51 VG is the first therapeutic vaccine against non-small cell lung cancer. This human-adjuvanted vaccine for prophylaxis is developed by employing innovative technologies.

Vaccine Adjuvant Market, by Geography:

Based on geography, the vaccine adjuvant market is primarily divided into North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

SPI Pharma Inc, GSK Plc, CSL Ltd, Seppic SA, Hawaii Biotech Inc, Dynavax Technologies Corp, InvivoGen SAS, Croda International Plc, Novavax Inc., and Phibro Animal Health Corp are the prominent vaccine adjuvant market players.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com